Interesting ImagesBreast Cancer Imaging With PET Based Radiopharmaceuticals Other Than 18F-FDGVatsa, Rakhee PhD; Singh, Shashank Shekhar DNB; Ashwathanarayana, Abhiram Gopalajois MD; Kumar, Rajender MD; Rana, Nivedita PhD; Shukla, Jaya PhD; Mittal, Bhagwant Rai MDAuthor Information From the Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Received for publication April 26, 2019; revision accepted July 21, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Bhagwant Rai Mittal, MD, Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: email@example.com. Online date: October 25, 2019 Clinical Nuclear Medicine: February 2020 - Volume 45 - Issue 2 - p e72-e76 doi: 10.1097/RLU.0000000000002783 Buy Metrics Abstract Breast cancer is the most common cancer in women with rising incidence worldwide. 18F-FDG PET/CT imaging has already established itself as a pivotal modality for staging, restating and response assessment in patients with carcinoma breast. The complex biology of this cancer is increasingly being decoded and various molecular targets have been identified and exploited for guiding the treatment at various time points during the course of the disease. We here depict a series of various metabolic and receptor targeting PET radiotracers in breast cancer patients which may help us understand the in vivo biology of this tumor. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.